Abstract
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
MeSH terms
-
Astrocytoma / drug therapy
-
Astrocytoma / enzymology
-
Astrocytoma / genetics
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / enzymology*
-
Brain Neoplasms / genetics*
-
Carcinoma / drug therapy
-
Carcinoma / enzymology
-
Carcinoma / genetics
-
DNA Mutational Analysis
-
Drug Resistance, Neoplasm / genetics
-
ErbB Receptors / genetics*
-
Gefitinib
-
Genetic Testing
-
Glioblastoma / drug therapy
-
Glioblastoma / enzymology
-
Glioblastoma / genetics
-
Glioma / drug therapy
-
Glioma / enzymology*
-
Glioma / genetics*
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Mutation / genetics*
-
Oligodendroglioma / drug therapy
-
Oligodendroglioma / enzymology
-
Oligodendroglioma / genetics
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Structure, Tertiary / genetics
-
Quinazolines / pharmacology
-
Quinazolines / therapeutic use
Substances
-
Protein Kinase Inhibitors
-
Quinazolines
-
ErbB Receptors
-
Gefitinib